@BadstuffLard @Izvestor I meant mostly the scatter shot recruitment. Simply that observations in less than ideal sub populations may prove helpful. In particular with say for instance tolerability within combo treatments down the road. My main problem with the trial design is that they misread their competitors as both Loxo and ARQL ran there’s like mini Phase IIs and as a result produced efficacy which was never possible within the constructs of SNSS’ trial
  • 88